Amyloidosis trials in Italy

In Italy 36 Also abroad 184

36 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
Where
Bologna, Ferrara, Florence, Genoa, Pavia, Pisa, Rome, Trieste
Age
18 years to 90 years
People
1,200 worldwide
Run by
Intellia Therapeutics
See details and how to joinNCT06128629 · EU 2023-507220-23-00
Phase 2Taking people
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis
Where
Naples, Pavia, Pisa
Age
18 years to 64 years
People
60 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07224672 · EU 2025-522803-60-00
No phaseNot yet taking people in Italy
Single-arm, Multi-center Study Evaluating the Acceptance and Feasibility of a Digital Remote Monitoring Tool Configured for Patients With ATTR-CM: ACO-Monitor
Where
Pavia
Age
18 years and over
People
60 worldwide
Run by
Bayer
See details and how to joinNCT07557147
Phase 3Enrolling by invitation
A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Where
Bologna, Florence, Pavia
Age
18 years and over
People
700 worldwide
Run by
Alnylam Pharmaceuticals
See details and how to joinNCT06679946
Phase 3Taking people
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
Where
Ancona - Torrette, Bologna, Bolzano, Brescia, Cona, Florence, Ivrea, Lecco, Messina, Milan, Naples, Orbassano, Palermo, Pavia, Perugia, Pisa, Roma, Rome, San Donato Milanese, Trieste
Age
18 years and over
People
1,280 worldwide
Run by
Novo Nordisk A/S
See details and how to joinNCT07207811
Phase 3Taking people
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Where
Ancona, Bologna, Brescia, Florence, Forli', Lecce, Milan, Naples, Padova, Pavia, Pisa, Rimini, Rome, Turin
Age
18 years to 85 years
People
1,750 worldwide
Run by
Alnylam Pharmaceuticals
See details and how to joinNCT07052903 · EU 2024-519917-72-00
No phaseTaking people
Edge-to-edge Mitral Valve Repair in ATTR-CM
Where
Bergamo, Brescia
Age
18 years and over
People
106 worldwide
Run by
Medical University of Vienna
See details and how to joinNCT06075823
Phase 4Taking people
A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to Acoramidis
Where
Bergamo, Bologna, Florence, Lecce, Milan, Naples, Padova, Pavia, Pisa, Siena
Age
18 years to 90 years
People
50 worldwide
Run by
Bayer
See details and how to joinNCT07298044 · EU 2025-521831-35-00
No phaseTaking people
ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
Where
Milan, Naples, Palermo, Roma
People
1,500 worldwide
Run by
Alnylam Pharmaceuticals
See details and how to joinNCT04561518
No phaseTaking people
Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program
Where
Pavia
People
10 worldwide
Run by
Alnylam Pharmaceuticals
See details and how to joinNCT05040373
Phase 3Taking people
TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
Where
Florence, Messina, Milan, Padova, Pavia, Rome
Age
18 years to 85 years
People
125 worldwide
Run by
Alnylam Pharmaceuticals
See details and how to joinNCT07223203 · EU 2025-522544-40-00
No phaseTaking people
A Study to Learn About the Use of Acoramidis in Patients With a Heart Condition Called Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in a Real-world Setting
Where
Multiple Locations
Age
18 years and over
People
2,000 worldwide
Run by
Bayer
See details and how to joinNCT07235462
No phaseTaking people
OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis
Where
Lecce, Messina, Milan
People
52,121 worldwide
Run by
AstraZeneca
See details and how to joinNCT06355934
No phaseTaking people
Echocardiographic Characterization of Cardiac Amyloidosis
Where
Roma
Age
18 years and over
People
255
Run by
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
See details and how to joinNCT05760287
Phase 3Not yet taking people in Italy
An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy
Where
Bologna, Ferrara, Florence, Forlì, Messina, Milan, Naples, Padova, Pavia, Pisa, Rome, Torino, Trieste
People
1,180 worldwide
Run by
Alexion Pharmaceuticals, Inc.
See details and how to joinNCT07789483 · EU 2026-526755-57-00
No phaseTaking people
Liver and Coagulation Disorders in Cardiac Transthyretin Amyloidosis
Where
Messina
Age
18 years and over
People
70
Run by
University of Messina
See details and how to joinNCT07766135
Phase 3Not yet taking people in Italy
To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)
Where
Bologna, Florence, Messina, Pavia, Pisa, Rome
Age
18 years and over
People
250 worldwide
Run by
Eidos Therapeutics, a BridgeBio company
See details and how to joinNCT07116473 · EU 2024-513676-18-00
Phase 3Taking people
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Where
Bologna, Florence, Messina, Pavia, Pisa, Rome
Age
18 years to 75 years
People
587 worldwide
Run by
Eidos Therapeutics, a BridgeBio company
See details and how to joinNCT06563895 · EU 2024-513547-82-00
Phase 1/2Taking people
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion
Where
Bologna, Pavia
Age
18 years and over
People
76 worldwide
Run by
AbbVie
See details and how to joinNCT06158854 · EU 2023-503429-20-00
No phaseTaking people
One Gene, Two Diseases: the Pathologic Role of IGLV1-44 in AL Amyloidosis and POEMS
Where
Pavia
Age
18 years to 99 years
People
100
Run by
Fondazione IRCCS Policlinico San Matteo di Pavia
See details and how to joinNCT07448935
Phase 3Enrolling by invitation
An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
Where
Ancona, Florence, Padova, Pavia, Pisa, Roma
Age
18 years and over
People
1,400 worldwide
Run by
Ionis Pharmaceuticals, Inc.
See details and how to joinNCT05667493
No phaseTaking people
A Registry of AL Amyloidosis (ReAL)
Where
Pavia
Age
18 years to 99 years
People
5,000
Run by
Fondazione IRCCS Policlinico San Matteo di Pavia
See details and how to joinNCT04839003
No phaseTaking people
A EUropean REgistry and Sample Sharing networK to Promote the Diagnosis and Management of Light Chain Amyloidosis (EUREKA)
Where
Pavia
Age
18 years to 99 years
People
400 worldwide
Run by
Fondazione IRCCS Policlinico San Matteo di Pavia
See details and how to joinNCT06205953
No phaseTaking people
NatiOnal Referral cenTEr Study of Transthyretin Amyloid Cardiomyopathy(ATTR) Patients on Tafamidis
Where
Pavia
Age
18 years to 99 years
People
200
Run by
Paolo Milani
See details and how to joinNCT06251778
No phaseTaking people
Promoting Diagnosis and Management of AL in Italy (ProDigALIty)
Where
Bari, Catania, Pavia, Torino
Age
18 years to 99 years
People
760
Run by
Fondazione IRCCS Policlinico San Matteo di Pavia
See details and how to joinNCT06383143